|11.35||-0.5100||-4.30%||Vol 909.24K||1Y Perf 277.71%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.25 2.20%|
|Target Price||16.13||Analyst Rating||Strong Buy 1.14|
|Potential %||42.11||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★ 57.16|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 48.25|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||86.61||Earnings Rating||—|
|Market Cap||1.43B||Earnings Date||10th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.17|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.18M|
|Avg. Monthly Volume||1.38M|
|Avg. Quarterly Volume||1.03M|
BELLUS Health Inc. (NASDAQ: BLU) stock closed at 11.35 per share at the end of the most recent trading day (a -4.3% change compared to the prior day closing price) with a volume of 909.24K shares and market capitalization of 1.43B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. BELLUS Health Inc. CEO is Roberto Bellini.
The one-year performance of BELLUS Health Inc. stock is 277.71%, while year-to-date (YTD) performance is 40.99%. BLU stock has a five-year performance of %. Its 52-week range is between 2.94 and 12.65, which gives BLU stock a 52-week price range ratio of 86.61%
BELLUS Health Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 3.51, a price-to-sale (PS) ratio of 81 762.60, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.72%, a ROC of -33.91% and a ROE of -34.44%. The company’s profit margin is -%, its EBITDA margin is -435 850.00%, and its revenue ttm is $11.79 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from BELLUS Health Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. BELLUS Health Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BELLUS Health Inc. is Strong Buy (1.14), with a target price of $16.13, which is +42.11% compared to the current price. The earnings rating for BELLUS Health Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BELLUS Health Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BELLUS Health Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.62, ATR14 : 0.73, CCI20 : 135.96, Chaikin Money Flow : 0.04, MACD : 0.65, Money Flow Index : 79.96, ROC : 22.04, RSI : 61.01, STOCH (14,3) : 63.98, STOCH RSI : 0.37, UO : 51.69, Williams %R : -36.02), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BELLUS Health Inc. in the last 12-months were:
Tue, 12 Jul 2022 15:15 GMT H.C. Wainwright Believes BELLUS Health (BLU) Wont Stop Here- TipRanks. All rights reserved.
Sat, 04 Jun 2022 09:02 GMT Analysts Are Bullish on Top Healthcare Stocks: BELLUS Health (BLU), Immutep Ltd (PRRUF)- TipRanks. All rights reserved.
Sun, 27 Feb 2022 10:51 GMT BELLUS Health (BLU) Receives a Buy from RBC Capital- TipRanks. All rights reserved.
Sun, 06 Feb 2022 14:06 GMT BELLUS Health (BLU) Receives a Buy from BTIG- TipRanks. All rights reserved.
Fri, 07 Jan 2022 01:56 GMT BELLUS Health (BLU) Received its Third Buy in a Row- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.